Cargando…
Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V(®))
Percutaneous coronary revascularization has been a mainstay in the management of coronary artery disease since its introduction in the late 1970s. Bare-metal stents and, more recently, first-generation drug-eluting stents (DES), such as sirolimus-eluting (Cypher(®)) and paclitaxel-eluting stents (Ta...
Autores principales: | Sheiban, Imad, Villata, Gianluca, Bollati, Mario, Sillano, Dario, Lotrionte, Marzia, Biondi-Zoccai, Giuseppe |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2464756/ https://www.ncbi.nlm.nih.gov/pubmed/18629361 |
Ejemplares similares
-
Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents
por: Lee, Da Hyon, et al.
Publicado: (2017) -
The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view
por: Sanchez, Oscar D, et al.
Publicado: (2014) -
Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010) -
Long‐term (beyond 5 years) clinical impact of Xience everolimus‐eluting stent implantation
por: Matsuda, Hiroaki, et al.
Publicado: (2021) -
A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study
por: Franzone, Anna, et al.
Publicado: (2017)